Pfizer Investing in Ireland’s Health

WelcomeThis report outlines Pfizer’s presence in Ireland and highlights our efforts to contribute to the overall health, growth and wellness of this country. We are continually reviewing and improving our efforts to lessen Pfizer’s impact on the environment, nurture a workplace of diversity and inclusion, conduct responsible business practices, and uphold the highest ethical standards in everything we do from research and development to sales and marketing.

As the world’s largest biomedical research and pharmaceutical company, Pfizer has a unique opportunity to be a good corporate citizen. Our role is to discover and develop medicines, help make medicines available, advance and share health information, and partner on public health programmes.

This report highlights some very worthy corporate social responsibility projects which Pfizer is involved in. From working directly with local charities to developing innovative environmental policies, the projects demonstrate Pfizer’s strong commitment to good corporate citizenship.

Our responsibilities and potential impact go far beyond the medicines we discover and develop. We believe that good corporate responsibility can be a source of business innovation. New partnerships that address social needs through business practices can foster sustainable healthcare solutions. Pfizer seeks these linkages so we can help make the world better for our communities, our key stakeholders, and for all those who want a healthier tomorrow.

Dr Paul Duffy Mr Paul ReidVice-President, Pfizer Managing Director, Pfizer Healthcare Ireland

1

2 3

Good health is vital to all of us, and finding sustainable solutions to the most pressing healthcare challenges of our world cannot wait. That’s why we at Pfizer are committed to applying science and our global resources to bring therapies to people that improve health and well-being at every stage of life.

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as some of the world’s best-known consumer healthcare products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference to all who rely on us.

Introduction Pfizer in IrelandPfizer employs approximately 3,200 people at six sites in Ireland across manufacturing, shared services, R&D, treasury and commercial operations. Pfizer has invested $7 billion in operations in Ireland since opening the first site in 1969 and has invested $330 million in the Grange Castle and Ringaskiddy sites in recent years. Many of Pfizer’s leading medicines are manufactured for global export from Irish sites. Part of Pfizer’s Worldwide Research & Development (WR&D) is based in Ireland: the Global Biotherapeutics Technology group at Grange Castle was established in 2006 and is part of a world-leading protein drug discovery unit within Pfizer Worldwide R&D.

• Pfizer’s activities in Ireland support around 10,700 jobs and result in €2.2 billion output into the Irish economy

• Ireland is a core country in Pfizer’s manufacturing network

• Pfizer Ireland is a leader in good corporate citizenship by actively supporting local communities and social projects nationwide

• Pfizer is one of Ireland’s leading employers and the largest pharmaceutical sector investor in the country

Pfizer GFSSPfizer Grange Castle

Pfizer Citywest

Pfizer Newbridge

Pfizer Ringaskiddy

Pfizer Little Island

4 5

Key Milestones for Pfizer in Ireland

Key Milestones for Pfizer in Ireland

Ringaskiddy plant opens. Pfizer becomes the first pharmaceutical manufacturing multinational company to locate in Ireland

Little Island plant opens

Treasury Centre opens in Dublin

Warner Lambert acquired providing additional manufacturing capacity

Pharmacia acquired providing an additional Irish manufacturingsite

$14 million investment in new R&D facility in Ringaskiddy

1969

1978

1991 2000

2003

2009

$7 billion invested in Ireland over 45 years

New manufacturing plant opens in Newbridge

$2.2 billion investment in state-of-the-artbiopharmaceutical campus at Grange Castle

$60 million investment in R&D at Grange Castle and Newbridge

October 2009 Pfizer acquires Wyeth

1992 2005

$444 million investment in Newbridge, expanding future production capabilities

2006

2007 2009

$200 million investment in the Grange Castle site to increase the manufacturing capacity for vaccines

Pfizer and Science Foundation Ireland (SFI) announced public-private partnership to encourage the discovery of potential new therapies.

$30 million investmentin the New Product Technology Laboratory (NPTL) at the Pfizer Ringaskiddy site

2011 2014

2013$100 million investment in the Grange Castle site in Dublin to create additional manufacturing capacity for therapeutic proteins

European Shared Services Centre opens in Dublin

2003

76

Pfizer working together for a healthier world

Innovate to bring therapies to patients that significantly improve their lives.

Our Purpose:

Innovation

8 9

Pfizer is prioritising its research and development efforts in areas where we can make the biggest difference to health and social care burdens: immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain, and vaccines. Through major research efforts across multiple modalities — including small molecules, biologics and vaccines — Pfizer is developing the medical solutions that will matter most to the people we serve. Specialised efforts in rare diseases also illustrate our dedication to developing and delivering innovative medicines and vaccines that will benefit patients around the world.

Clinical InnovationPfizer has taken a leadership position in creating a discipline around Clinical Innovation, ensuring we are taking advantage of cutting-edge tools, approaches and partnerships to ensure our clinical trials are executed with optimal quality, speed and agility. Pfizer’s Clinical Innovation investments and initiatives are focused on patient engagement, making work easy for sites and leveraging real world data.

Integrated Regulatory & SafetyPatient safety is a paramount concern for Pfizer, from the moment a new compound is discovered and for as long as a medicine is prescribed. It is our ethical and regulatory responsibility to monitor the safety of our medicines everywhere they are marketed. Once a drug compound is approved, we continue to monitor its safety and work with governments and others to secure the supply chain and take appropriate action on counterfeiting.

Scientific InnovationA critical part in the process of bringing new therapies to patients is clinical development — the study of potential new therapies in humans. Pfizer’s R&D division works in partnership with hundreds of collaborators, including some of the world’s top researchers and scientists in academia, healthcare, government and the biopharmaceutical industry. We prioritise and focus our R&D efforts on areas where we can make the biggest difference to health and social care burdens: immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain, vaccines, rare diseases and biosimilars.

Broadening Access to Information from Clinical TrialsTransparency is essential to trust, and Pfizer has taken a leadership role in the industry concerning the access and sharing of clinical trial results. Recently, we announced a policy that simplifies and broadens access to information gathered in Pfizer-sponsored clinical trials. While for several years we have published the results of clinical trials we file with regulators, this expanded policy enables the sharing of anonymous patient-level data from recent Pfizer-sponsored studies with qualified investigators outside the company, upon their request. We are also providing, in easy-to-understand language, information on clinical trial results to study participants.

Creating an Ecosystem of InnovationExternal collaboration is critical to advancing our R&D strategy and expediting new medical breakthroughs. We continue to work with a broad array of organisations to connect the assets and capabilities that have the potential to speed the development of new medicines for patients.

Key to expediting the translation of science into breakthrough therapies of tomorrow will be driving greater, deeper and stronger collaborations across the healthcare landscape. The Global Biotherapeutics Technologies group (GBT) is a primary biotherapeutic drug discovery and development group housed both at Grange Castle and at our sister site in Cambridge Massachusetts. GBT is responsible for the discovery and molecular engineering of novel protein therapeutics for use in all indications being researched by Pfizer Worldwide Research & Development Units.

PartnershipsCollaboration is fundamental to our strategy - we see the value in fostering relationships between industry and academia by working with more than 250 academic partners globally. In Ireland we work closely with academia through state-funded initiatives such as the Solid State Pharmaceutical Cluster (SSPC). SSPC is an innovative collaboration between academic researchers and leading pharmaceutical companies, spearheaded by the University of Limerick. The cluster provides the necessary skill set for the pharmaceutical industry and academic institutions to comprehensively investigate pharmaceutical solids. Pfizer is also a founding corporate partner of the College of Medicine and Health at University College Cork. Funding for this partnership focuses on delivering patient care as well as research and innovation.

In Novermber 2012 we joined the prestigious Science Circle at the Science Gallery, Trinity College Dublin. Pfizer, in partnership with other leading global companies, supports the Science Gallery’s yearly programmes at Trinity College Dublin and fosters the development of science in Ireland.

The Science Foundation Ireland (SFI) and Pfizer announced a unique partnership that aims to promote new biotherapeutic breakthroughs in Ireland, through an academic-industry collaboration. The three year agreement will be available to qualified academic researchers from Irish universities with novel drug targeting ideas. Successful applicants will have the opportunity to work with the Pfizer Global Biotherapeutics Technology (GBT) group, including Pfizer colleagues at the Pfizer Grange Castle site, in an effort to develop the next generation of potential protein therapies. This will enable the blending of the research expertise of academics with Pfizer’s drug discovery and development expertise and resources. It is hoped this collaboration will identify exciting new advances that may lead to the accelerated creation of potential new therapies for unmet medical needs.

Our Commitment to Science

Dr Paul Duffy, Vice-President, Pfizer; Mr Seán Sherlock, TD, Minister for Research and Innovation and Mr Seamus Fives, Site Leader, Ringaskiddy and Little Island

Prof John Higgins, Head of College of Medicine and Health, UCC; Dr Michael Murphy, President, UCC; Ms Mary Horgan, Dean and Head of School of Medicine, UCC and Dr Paul Duffy, Vice-President, Pfizer, at the announcement of Pfizer’s corporate sponsorship of the College of Medicine and Health, UCC

Dr William Finlay, Director of Global Biotherapeutics Technologies, Pfizer; Dr Paul Duffy, Vice-President, Pfizer; Mr Seán Sherlock, TD, Minister for Research and Innovation and Prof Mark Ferguson, Director General, Science Foundation Ireland (SFI)

Mr Nick Bevan, Multi Product Capability Project Lead, Pfizer; Mr Simon Orchard, Vice-President, Product Portfolio Management, Pfizer; Ms Frances Fitzgerald, TD for Dublin Mid-West, Minister for Children and Youth Affairs; Dr Paul Duffy, Vice-President, Pfizer; Mr Richard Bruton, TD, Minister for Jobs, Enterprise and Innovation; Mr Barry O’Leary, CEO, IDA; Mr Julien Deneve, Site Leader, Pfizer Grange Castle

Corporate Citizenship

10 11

Our Responsibility in a Changing WorldAt Pfizer, we think of corporate responsibility simply as how we do business. We believe that improving our impact on Irish society strengthens our company and fulfils our business purpose – to bring therapies to people that significantly improve their lives. In partnership with Irish public and private institutions, foundations, non-government organisations, and governments, we are working to meet the health needs of the underserved while investing in the health of our communities and in the health of our business.

We strive to positively impact the health of people in Ireland, focusing on investing the full range of the company’s resources — people, skills, expertise and funding — to broaden access to medicines and strengthen healthcare delivery for underserved people. Our philanthropy platform offers a coordinated approach to contribute to society beyond medicines:

• Treat: Improving access to medicines and healthcare services

• Teach: Expanding healthcare worker training and patient education on disease prevention and treatment options

• Build: Strengthening the capacity of healthcare organisations to support prevention, diagnosis, treatment and care

• Serve: Advocating and sharing best practices to improve healthcare for the underserved

Working together to make a difference globally

Working to Accelerate Access to Pfizer Vaccines in the Developing World

Today, more people benefit from safe and effective vaccines than ever before. We are committed to helping protect millions of infants and young children in the developing world from pneumococcal disease; the leading cause of vaccine-preventable death in young children. Also in 2013, Pfizer and the GAVI Alliance (formerly the Global Alliance Vaccines and Immunization) announced Pfizer’s commitment to supply up to an additional 260 million doses of vaccine to help protect infants and young children in the world’s poorest countries from pneumococcal disease. Pfizer’s Advance Market Commitment supply agreements with GAVI now encompass up to 740 million doses of pneumococcal vaccine through 2025, made available on an accelerated, affordable and sustainable basis to help reduce morbidity and mortality from pneumococcal disease and prevent an estimated 7 million childhood deaths by 2030.

Working to Reduce Impact of HIV/AIDS Related Opportunistic Infections

Increased access to HIV and AIDS treatment has improved the prognosis for many HIV-infected patients. However, many patients continue to die of HIV-related opportunistic infections. In sub-Saharan Africa alone, there are more than 500,000 deaths each year due to cryptococcal meningitis (source: World Health Organization, 2011). Since 2000, Pfizer and its partners have distributed millions of anti-fungal treatments for two AIDS-related fungal infections – cryptococcal meningitis and oesophageal candidiasis – free of charge to to more than 2,600 sites in 63 countries in Africa, Asia, the Caribbean and Latin America.

Working to Eliminate Blinding Trachoma

Pfizer is a founding partner of the International Trachoma Initiative (ITI), a global programme that recently marked its 15th anniversary of working to eliminate blinding trachoma as a public health concern. Through the ITI, we have donated more than 340 million doses of an appropriate antibiotic to prevent and treat trachoma in support of the World Health Organization-led Global Alliance for the Elimination of Trachoma by the year 2020.

Working to Advance Research in Neglected Diseases

WIPO Re: Search is an R&D consortium dedicated to developing new solutions — including medicines, vaccines and diagnostics — for neglected tropical diseases, malaria and tuberculosis. The consortium, which was launched in 2011, has over 80 members, 44 research agreements in place and has facilitated five arrangements whereby developing country scientists are hosted by developed country members of WIPO Re:Search. Pfizer is involved in several agreements where we are making specific contributions to advance external research programmes targeting diarrhoea, dengue fever and cerebral malaria.

Working To Improve Health in Underserved Communities

Global Health Investment Fund (GHIF) is a first-of-its-kind fund that will finance late-stage global health technologies that have the potential to save millions of lives in low-income countries. GHIF will help advance the most promising interventions to fight challenges such as malaria, tuberculosis, HIV/AIDS, and maternal and infant mortality, while expanding access to healthcare and fostering new possibilities that come from improved health in underserved communities. To help fill the funding gaps for late-stage clinical trials and development expenses, GHIF will invest in new drug and vaccine candidates, emerging diagnostic tools, child-friendly formulations of existing products, expanding manufacturing capacity and other applications that will help bring affordable technologies to those most in need.

The Pfizer Foundation has committed a $5 million investment in GHIF as part of $108 million in initial financing for the fund, which was developed by The Bill & Melinda Gates Foundation, JPMorgan Chase & Co. and Lion’s Head Global Partners.

Working Together to Make a Difference in IrelandWe strive to be a trusted and responsible member of the communities in which we work and live. We do this by going beyond the business of discovering and developing medicines to give back to our communities through urban revitalisation, school partnerships and support for local civic and cultural institutions.

Here is a selection of some of the activities that Pfizer colleagues have undertaken in Ireland:

Plato programme

Collected for Arthritis Ireland

Do a Dish for Make a Wish

Barnardos Toy Appeal

Irish Cancer Society’s Daffodil Day

Healthy Town Project I

ce

Cream

Day

Annual Volunteer Day

Junior Achievement in Schools

Men’s Health and Wellbeing Programme

Movember

Children’s Medical and Research Foundation

Science Week

Transition Year Programmes

Young Social

Laura Lynn Foundation

Alzheimer’s Ireland Tea Party

Enterprisev e n i n g s

Kids

2

Work

Day

InnovatorsRelay for Life

12 13

14 15

CollaborationThe Global Health Fellows Programme is our global volunteer programme through which the company pairs Pfizer colleagues with leading international health organisations to strengthen health service delivery. Fellows are immersed in three to six month specialised assignments, working hand-in-hand with community-based partners to help improve healthcare systems while gaining new perspectives on global health challenges and how the public and private sector can work together to address them.

The GHF programme has been recognised as a “best-in-class” programme model for its impact on global health, as well as its value to Pfizer colleagues and the business. To date, more than 350 colleagues have completed an estimated 345,000 hours in skills based pro bono service, valued at almost $50 million with local partners, throughout the developing world.

Pfizer Ireland is proud to recognise three Irish colleagues who have participated in the GHF programme to date.

Albert DunneShared Services Project Lead at Pfizer Global Financial Shared Services, Ringsend, Dublin

As part of his service as a Global Health Fellow in 2012, Albert spent four months on assignment working with IntraHealth International in Nairobi, Kenya to assist with initiatives focused on human resource and change management.

IntraHealth International works to champion health workers. The organisation collaborates with governments, NGOs, the private sector, and other organisations to foster policies that empower health workers to better serve communities in need.

The main focus of Albert’s placement was to project manage the implementation of a Human Resource Information System (iHRIS) at two health facilities in Nairobi.

Kathy O’KellyDirector Quality Systems & Compliance (QS&C) Validation at Pfizer Grange Castle, Clondalkin, Dublin

Kathy’s four month fellowship assignment was based in Nairobi, Kenya, with a non governmental organisation called Management Sciences for Health.

The programme that Kathy served was the Health Commodities and Services Management (HCSM) programme which focused on working with the Kenyan government to improve the supply chain for medicines and health commodities across the country.

Her goal was to work with the HCSM team to develop a concept paper for a nationally harmonised logistics MIS for all health commodities (medicines, test kits etc.) in the public sector in Kenya. This concept paper was developed and presented to the Kenyan Ministry of Health for consideration and implementation.

Roger Rice

BT Business Partner/Project Manager at Pfizer Global Financial Shared Services, Ringsend, Dublin

Roger’s four month fellowship assignment was to act as Capacity Manager looking at Organisational Development for Save the Children (STC) and their non-governmental organisation (NGO) partners in Addis Ababa, Ethiopia. STC works with a network of small community-based non-profit organisations to deliver HIV prevention and care services to highly at-risk populations including labourers and transport workers.

Roger had the opportunity to work with Boston University and 12 of STC’s partnering non-governmental organisations who were selected as part of the TransACTION programme. The

TransACTION programme was established to help prevent new HIV infections among at risk populations and strengthening linkages to care and support services in towns and commercial hotspots along or linked with major transportation corridors.

One of Roger’s main objectives was to review and redesign STC’s TOCAT (TransACTION Organisational Capacity Assessment Tool). The TOCAT tool is a participatory organisational assessment tool whereby employees are given the opportunity to provide their input on performance of their organisation. The results of the assessment indicated where efforts were most needed and assisted the organisations with the development of recommendations, training etc.

Based on these priorities, Roger concentrated on developing training packs and materials which could be delivered to the management teams of STC’s partners. Additionally, he also provided training and guidance on 6 Sigma tools that could be applied in simply improving other organisational areas such as Finance and HR. In addition, Roger trained the capacity management team to support the work and continue to deliver such training to partnering NGOs of STC.

16 17

Well-beingOne of Pfizer’s core commitments is to improve health and well-being at every stage of life. As well as discovering and developing medicines, we work with community groups, individuals and health consumer organisations to enhance public health in local communities. One innovative example of our commitment to the well-being in local communities is the ‘Healthy Town’ project.

‘Healthy Town’ is an innovative collaboration between The Irish Times, Pfizer Healthcare Ireland and the civic and business community of a chosen Irish town. ‘Healthy Ireland’, the national framework for action to improve the health and well-being of Ireland, supports the initiative.

‘Healthy Town’ aims to improve the health and well-being of the population of a town by showing the local community how simple adjustments can make a real difference to their health.

The eight-week programme combines health promotion events, information meetings, health checks and physical activity sessions, to encourage the people of a town to improve their health, with all events free of charge. Key features of the ‘Healthy Town’ include:

• Free one to one health checks provided by the Irish Heart Foundation through local groups to members of the public

• Talks and demonstrations from expert speakers on areas including healthy eating, parenting, mental health, relationships, stress management and health promotion

• Healthy shopping and nutrition tours given by Irish Heart Foundation dietitians in local supermarkets

• Numerous sports and fitness activities throughout the eight-week period for people of all ages and abilities

The success of previous ‘Health Town’ initiatives can be attributed to the support of many local groups and businesses in the hosting and promotion of such events. This ensures wide awareness and participation in the events and activities throughout the full eight-week programme. The partnerships and collaborations have also left lasting legacies in the towns that have taken part in the initiative. For example, as a result of the Healthy Town programme in Wicklow, the local Council opened a 7.6km walkway to mark the town’s participation in ‘Healthy Town’.

The inaugural ‘Healthy Town’ project took place in Kilkenny in 2012 and since then the initiative has been hosted by Wicklow in 2013 and Portlaoise in 2014. ‘Healthy Town’ continues to build on each year’s success and has made a significant impact on the towns that have hosted the project to date. In the past three years, hundreds of members of ‘Healthy Town’ communities have received health screenings and learned about how to improve their long term health through participation in the project’s various events and activities.

Photographs courtesy of The Irish Times

Potential

18 19

Pfizer Ireland is committed to nurturing young people’s talents and to promoting science and innovation in Ireland’s schools. We aim to inspire younger generations to continue to innovate and work to their full potential, to learn about the activities at Pfizer and to be aware of the many opportunities that exist in science and engineering.

Every Pfizer site in Ireland has made connections with local schools to offer learning opportunities to both primary and secondary level students. Sites organise and deliver a variety of education projects which offer students a “real life” insight into science and engineering from a young age. These initiatives range from nature projects for very young children to engineering programmes for senior cycle students.

Pfizer Newbridge offers an exciting array of such learning opportunities specifically aimed at junior school pupils. The ‘Nature at Newbridge Nest Box Project’ is an environmental education project concentrated on the grounds of the Newbridge site. Working with BirdWatch Ireland, local primary school children attend workshops on the grounds where they learn about local birdlife and participate in practical experiments. The project encourages the children to take an interest in their local wildlife and provides an opportunity to practice what they have learned in terms of protecting and nurturing our native species.

Pfizer Newbridge also provides various practical learning initiatives for second level students in the surrounding area. The “Engineering Week” initiative is carried out in collaboration with Engineers Ireland and local second level colleges.

Students are invited to the site for an in-depth look at the various operations at the plant. Students tour the facility, receive presentations on engineering techniques and advancements in operations and learn about the site’s green technologies and energy efficiency programmes. In addition, participants attend career workshops where colleagues share their career journey stories with the pupils. Colleagues from the Engineering Services, Shift Engineer and Technician groups devoted 60 hours to this project including hours of their personal time. Colleagues in Grange Castle have been involved in this project for the last number of years.

Building on the success of projects such as these, Pfizer Ireland continues to develop new initiatives each year to inspire young people, particularly in the fields of science and engineering.

A Sustainable Future

20 21

Our commitment to advancing health includes being good stewards of the environment. We constantly assess our business practices and advance those that we believe produce measurable value for society and our business, while minimising risk to our shareholders. Our strategic approach focuses on reducing energy and water consumption in addition to innovative ways to manage waste.

Our “green journey” focuses on three areas key to our business:

ENERGY — mitigating climate change and its impacts

WASTE — minimising the environmental impact of our products and processes

WATER — managing water resources sustainably

Building on a Strong RecordYear on year Pfizer demonstrates a strong record in reducing greenhouse gas emissions. We are an acknowledged leader in Green Chemistry, having made significant solvent and waste reductions, for more than a decade, by investing in safer chemistry pathways that result in greener processes.

Product StewardshipPfizer evaluates and manages risk throughout the product life-cycle. We have an active programme to assess and address the issues associated with pharmaceuticals in the environment (PIE) and unused medicines.

Manufacturing and Supply ChainPfizer is committed to supplying products to patients that significantly improve their lives. Therefore, our manufacturing and supply division focuses on ensuring that all Pfizer products are produced to the highest standards of quality, safety and efficacy and are available when needed.

Quality and ComplianceEnsuring high-quality medicines and drugs requires vigilance and a strong quality culture. Product quality is everyone’s responsibility at Pfizer. We work diligently to supply our products in full compliance with all applicable legal requirements everywhere we work and, just as importantly, to our own high standards worldwide.

We are equally diligent about making certain that our products transit from plant to patient in a safe, secure and compliant manner to ensure quality and patient safety. Transporting and distributing medicines requires well designed procedures that address the particular handling requirements for each product class, such as temperature control, controlled substances legislation and environmental management.

Supply Chain SecurityAs an industry-recognised leader in supply chain security, Pfizer developed a dedicated security programme that encompasses every part of the manufacturing and delivery process, starting with the procurement of raw materials and continuing through to the delivery of product to the point of dispensation to our customers. As global pharmaceutical supply chains become increasingly complex, we see supply chain security as a growing and critical component of our commitment to patient safety and to the prevention of adulterated or counterfeited drugs entering the healthcare system. We have been open and active advocates for legislation designed to improve the security and safety of the global pharmaceutical supply chain.

Pfizer in Ireland is acutely aware of the need to care for and preserve our natural resources. We bring our environmental awareness to all stages of planning, set-up and operations of our manufacturing plants. We are continually reviewing and improving our efforts to lessen our impact on the environment, by identifying emerging Environment, Health and Safety (EHS) issues relevant to our industry and stakeholders. As a business we recognise and welcome the greater responsibilities that come with scope and scale, and consider EHS a key pillar of good corporate citizenship.

Pfizer leads efforts to address EHS through innovative policies and programmes such as the award winning Green Journey project at the Pfizer Grange Castle site. The Green Journey was a project to facilitate the sharing of successful projects and practices between each of the manufacturing sites. Each site could then evaluate how the project could be replicated to further reduce the environmental impact of their activities.

This project was the overall category winner in the Green Awards 2011, Large Manufacturer category. Eight colleagues participated in the organisation of this project which has been repeated four times. In addition, Pfizer was a finalist in the Green Awards in 2009, 2010 and 2012.

Pfizer operates to industry standard ISO 14001 TWM (Total Waste Management) across Ireland, to share best practice, promote innovation and reduce and eliminate waste. The Green Journey demonstrates the collective impact that the Pfizer manufacturing sites in Ireland are making to protect the local environments in which they operate and the collective contribution being made to reduce the impact of our manufacturing on climate change and loss of habitat.

Pfizer Ireland’s Green Journey

22

Since Pfizer was founded by cousins Charles Pfizer and Charles Erhart in 1849, our pharmaceutical company has remained dedicated to discovering and developing new, and better, ways to prevent and treat disease and improve health and well-being for people around the world. Headquartered in New York, today we are the world’s largest biopharmaceutical company, with a broad and diversified global product portfolio, and leadership in virtually all key high-growth therapeutic areas.

Good health is vital to all of us, and finding sustainable solutions to the most pressing healthcare challenges of our world cannot wait. That’s why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related healthcare services to the people who need them.

We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer’s disease and cancer.

To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in healthcare decisions. Through working in partnership with everyone from patients to healthcare providers and managed care organisations to world governments and non-governmental organisations, our goal is to ensure that people everywhere have access to innovative treatments and quality healthcare.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading Biopharmaceutical Company, we also collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

About Pfizer Inc.

23

Awards

24

2010• Facility of the Year Award Winner for Facility Integration at the International Society for Pharmaceutical Engineering

Awards (ISPE).• Winner of “Best People Development Initiative” at the Institute of Purchasing and Material Management (IIPMM)

National Procurement Awards.

2011• Winner of the “Large Manufacturing” category award at the Green Awards Chambers Ireland CSR Award for Pfizer’s

Green Journey.• Winner “Energy Awareness Award” at the Sustainable Energy Awards.

2012• Awarded the Business Working Responsibly Mark, Ireland’s only certification for responsible and sustainable practices.

• Winner of the National Irish Safety Organisation (NISO) Chemical & Pharmaceutical Manufacturers Safety Award.

2014• Winner of the Treasury Today Adam Smith Award for Best Practice and Innovation in the “Best Process Re-engineering”

category.

• Winner Facility of the Year at the International Society of Pharmaceutical Engineering Awards.

• Awarded the “Operational Excellence Award” by the International Society for Pharmaceutical Engineering.

• Awarded the Business Working Responsibly Mark, Ireland’s only certification for responsible and sustainable practices.

• Mr Dave Cagney, Site Lead, Pfizer Newbridge honoured with Pharmaceutical Leader of the Year at the inaugural Pharma Industry Awards.

• Pfizer Ireland named winner of the Pharmaceutical Company of the Year at the inaugural Pharma Industry Awards.

Ms Fiona O’Leary, Head of IT and Banking Process; Ms Susan Webb, Managing Director and Mr Raj Ramapatna, Treasury Technology Lead, all of Pfizer Dublin Treasury Centre.

Mr Dave Cagney, Site Lead, Pfizer Newbridge honored with Pharmaceutical Leader of the Year at the inaugural Pharma Industry Awards.

Mr Paul Reid, Country Manager Pfizer Healthcare Ireland, pictured at the BITC Business Working Responsibly Award.

Accepting the ISPE Facility of the Year Award are Pfizer Grange Castle colleagues (L-R) Mr Ed O’Leary, Mr George Skillin, Mr Brian Gleeson, Mr Guy McDonnell, Mr Greg Ubben and Mr Justin DePauw.

Pfizer colleagues proudly accept the Pharmaceutical Company of the Year award at the Pharma Industry Awards.

Ms Joan Burton, TD, Tánaiste and Minister for Social Protection, Ms Karen O’Keeffe, Director of Corporate Affairs Pfizer Ireland, and Mr Kieran McGowan, Chairperson of Business in The Community (BITC). Pfizer Ireland was awarded the BITC Business Working Responsibly Mark.

Contact Information

Pfizer Healthcare Ireland9 RiverwalkNational Digital ParkCiywest Business CampusDublin 24

Pfizer Ireland Pharmaceuticals Grange Castle Business ParkClondalkinDublin 22

Pfizer NewbridgeNewbridgeCo. Kildare

Pfizer Ireland PharmaceuticalsRingaskiddy Active Pharmaceutical Ingredient PlantRingaskiddyCo. Cork

Pfizer Ireland PharmaceuticalsLittle Island Active Pharmaceutical Ingredient PlantLittle IslandCo Cork

Global Financial Solutions, EuropeThe Watermarque BuildingRingsendDublin 4